Cardiovascular manifestations and treatment considerations in COVID-19

  • Yu Kang
    Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
  • Tiffany Chen
    Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
  • David Mui
    University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
  • Victor Ferrari
    Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
  • Dinesh Jagasia
    Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
  • Marielle Scherrer-Crosbie
    Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
  • Yucheng Chen
    Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China
  • Yuchi Han
    Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

書誌事項

公開日
2020-04-30
権利情報
  • http://creativecommons.org/licenses/by-nc/4.0/
DOI
  • 10.1136/heartjnl-2020-317056
公開者
BMJ

この論文をさがす

説明

<jats:p>Since its recognition in December 2019, covid-19 has rapidly spread globally causing a pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are associated with a greater severity and higher fatality rate of covid-19. Furthermore, COVID-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. The cardiovascular interactions of COVID-19 have similarities to that of severe acute respiratory syndrome, Middle East respiratory syndrome and influenza. Specific cardiovascular considerations are also necessary in supportive treatment with anticoagulation, the continued use of renin-angiotensin-aldosterone system inhibitors, arrhythmia monitoring, immunosuppression or modulation, and mechanical circulatory support.</jats:p>

収録刊行物

  • Heart

    Heart 106 (15), 1132-1141, 2020-04-30

    BMJ

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ